Homepage
Healthcare · Drug Manufacturers - Specialty & Generic · United States · Updated May 11, 1:53pm
$35.97
Price
$1.5B
Market Cap
1,940
Employees
0.61
Beta
Jack Clifford Bendheim
CEO
Business Description
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
Business History
Price Overview
Last updated: May 11, 2026 1:53pm (just now)$35.97
-4.03 (-10.08%)
Day Range
$35.08 – $39.85
52-Week Range
$22.51 – $60.08
50-Day MA
$53.63
200-Day MA
$43.10
Volume
535,506.53
Analyst Price Targets
Low
$49.00
Consensus
$49.00
High
$49.00
(7 analysts)
Share Structure
Outstanding
40,538,416.00
Float
40,238,472.00
Free Float
99.3%
High free float
— 99.3% of shares trade freely, ~0.7% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
15.32
Stock Price: $35.97
EPS (Diluted): 1.19
EPS (Diluted): 1.19
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.62
Stock Price: $35.97
Total Equity: $285.68M
Shares: 40,700,000
Total Equity: $285.68M
Shares: 40,700,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
9.32
Market Cap: $1.46B
Total Debt: $718.69M
Cash: $68.04M
EBITDA: $146.85M
Total Debt: $718.69M
Cash: $68.04M
EBITDA: $146.85M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$2.2B
Market Cap: $1.46B
Total Debt: $718.69M
Cash: $68.04M
Total Debt: $718.69M
Cash: $68.04M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
30.9%
Gross Profit: $399.94M
Revenue: $1.30B
Revenue: $1.30B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
8.5%
Operating Income: $110.47M
Revenue: $1.30B
Revenue: $1.30B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
3.7%
Net Income: $48.26M
Revenue: $1.30B
Revenue: $1.30B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
29.5%
Net Income: $48.26M
Total Equity: $285.68M
Total Equity: $285.68M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
11.2%
Operating Income: $110.47M
Tax Rate: 29.0%
Equity: $285.68M
Total Debt: $718.69M
Cash: $68.04M
Tax Rate: 29.0%
Equity: $285.68M
Total Debt: $718.69M
Cash: $68.04M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
3.17
Current Assets: $810.61M
Current Liabilities: $293.47M
Current Liabilities: $293.47M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
2.52
Short-Term Debt: $16.25M
Long-Term Debt: $702.44M
Total Debt: $718.69M
Total Equity: $285.68M
Long-Term Debt: $702.44M
Total Debt: $718.69M
Total Equity: $285.68M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$31.85
Revenue: $1.30B
Shares: 40,700,000
Shares: 40,700,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$7.02
Total Equity: $285.68M
Shares: 40,700,000
Shares: 40,700,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$1.03
Operating CF: $80.12M
CapEx: -$38.29M
Shares: 40,700,000
CapEx: -$38.29M
Shares: 40,700,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
1.9%
Last Dividend: N/A
Stock Price: $35.97
Stock Price: $35.97
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $48.26M
Net Income: $48.26M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares PAHC against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $833.4M | $942.3M | $977.9M | $1.0B | $1.3B |
| Cost of Revenue | $562.0M | $656.9M | $679.7M | $704.6M | $896.3M |
| Gross Profit | $271.4M | $285.4M | $298.2M | $313.1M | $399.9M |
| Operating Expenses | $196.5M | $206.4M | $226.4M | $259.8M | $289.5M |
| Operating Income | $74.9M | $79.0M | $71.8M | $53.3M | $110.5M |
| Net Income | $54.4M | $49.2M | $32.6M | $2.4M | $48.3M |
| EBITDA | $110.2M | $117.1M | $106.0M | $69.1M | $146.8M |
| EPS | $1.34 | $1.21 | $0.81 | $0.06 | $1.19 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $50.2M | $74.2M | $41.3M | $70.6M | $68.0M |
| Total Current Assets | $498.9M | $566.2M | $585.7M | $601.0M | $810.6M |
| Total Assets | $841.3M | $931.7M | $971.4M | $982.2M | $1.4B |
| Current Liabilities | $164.1M | $190.8M | $176.0M | $204.1M | $293.5M |
| Long-Term Debt | $382.7M | $417.9M | $452.5M | $458.3M | $702.4M |
| Total Liabilities | $602.8M | $669.3M | $688.9M | $725.5M | $1.1B |
| Total Equity | $238.5M | $262.4M | $282.5M | $256.6M | $285.7M |
| Retained Earnings | $218.0M | $247.7M | $260.9M | $243.9M | $272.7M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $48.3M | $31.6M | $13.3M | $87.6M | $80.1M |
| Capital Expenditure | -$29.3M | -$37.0M | -$51.8M | -$41.2M | -$38.3M |
| Free Cash Flow | $19.0M | -$5.4M | -$38.5M | $46.4M | $41.8M |
| Acquisitions (net) | $29.3M | -$13.5M | $0 | -$3.3M | -$286.5M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $13.9M | $24.0M | -$33.0M | $29.3M | -$2.6M |
Analyst Estimates (Annual)
| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue |
$1.3B $1.3B – $1.3B
|
$1.5B $1.5B – $1.5B
|
$1.5B $1.5B – $1.6B
|
$1.6B $1.6B – $1.6B
|
| EBITDA |
$139.6M $138.5M – $140.2M
|
$163.0M $162.1M – $163.7M
|
$168.9M $167.8M – $170.0M
|
$174.8M $174.8M – $174.9M
|
| Net Income |
$82.7M $81.9M – $83.5M
|
$123.9M $121.4M – $126.3M
|
$137.0M $129.0M – $145.0M
|
$152.6M $151.6M – $153.6M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +13.1% | +3.8% | +4.1% | +27.4% |
| Gross Profit Growth | +5.2% | +4.5% | +5.0% | +27.7% |
| Operating Income Growth | +5.5% | -9.0% | -25.8% | +107.2% |
| Net Income Growth | -9.6% | -33.7% | -92.6% | +1,897.7% |
| EBITDA Growth | +6.3% | -9.5% | -34.9% | +112.6% |
Dividend History (Last 20)
| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-03 | $0.12 | 2026-05-05 | 2026-06-03 | 2026-06-24 |
| 2026-03-04 | $0.12 | 2026-02-03 | 2026-03-04 | 2026-03-25 |
| 2025-11-26 | $0.12 | 2025-11-04 | 2025-11-26 | 2025-12-17 |
| 2025-09-03 | $0.12 | 2025-07-29 | 2025-09-03 | 2025-09-24 |
| 2025-06-04 | $0.12 | 2025-05-06 | 2025-06-04 | 2025-06-25 |
| 2025-03-05 | $0.12 | 2025-02-04 | 2025-03-05 | 2025-03-26 |
| 2024-11-27 | $0.12 | 2024-11-05 | 2024-11-27 | 2024-12-18 |
| 2024-09-04 | $0.12 | 2024-07-30 | 2024-09-04 | 2024-09-25 |
| 2024-06-05 | $0.12 | 2024-05-07 | 2024-06-05 | 2024-06-26 |
| 2024-03-05 | $0.12 | 2024-02-06 | 2024-03-06 | 2024-03-27 |
| 2023-11-28 | $0.12 | 2023-11-06 | 2023-11-29 | 2023-12-20 |
| 2023-09-05 | $0.12 | 2023-07-25 | 2023-09-06 | 2023-09-27 |
| 2023-06-06 | $0.12 | 2023-05-01 | 2023-06-07 | 2023-06-28 |
| 2023-02-28 | $0.12 | 2023-02-06 | 2023-03-01 | 2023-03-22 |
| 2022-11-29 | $0.12 | 2022-11-07 | 2022-11-30 | 2022-12-21 |
| 2022-09-06 | $0.12 | 2022-07-25 | 2022-09-07 | 2022-09-28 |
| 2022-05-31 | $0.12 | 2022-05-02 | 2022-06-01 | 2022-06-22 |
| 2022-03-01 | $0.12 | 2022-02-07 | 2022-03-02 | 2022-03-23 |
| 2021-11-23 | $0.12 | 2021-11-01 | 2021-11-24 | 2021-12-15 |
| 2021-08-31 | $0.12 | 2021-07-26 | 2021-09-01 | 2021-09-22 |
No community reviews yet for PAHC.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27